Vasculonics develops new therapy for acute kidney and chronic diabetic kidney disease with clinical candidates
Vasculonics is an Indiana-based biotech formed out of technology licensed from Indiana University.
Based on the novel discoveries of Dr. Jaipal Singh, Vasculonics is pioneering the development of therapeutics affecting the dimethylarginine dimethylaminohydrolase (DDAH) which reduces asymmetric dimethyl arginine (ADMA) and vascular pathology in kidney, heart and lungs (including pulmonary arterial hypertension).
Reduced levels of DDAH, common from stressors like diabetes, CV disease, and lung dysfunction, leads to the accumulation of high levels of ADMA. ADMA has been identified as a major cause of reducing nitric oxide (NO) synthesis, induction of mitochondrial dysfunction, cell death, inflammation, and fibrosis.
Vasculonics has developed proof of concept (POC) that restauration of DDAH by administering exogenous DDAH is therapeutic. Vasculonics is also developing novel small molecules which enhance DDAH expression. POC has been achieved in a broad range of in vitro and in vivo models.
Vasculonics is developing a IV biomolecule for acute kidney injury and an oral molecule for diabetic kidney disease toward an IND filing for first in man studies, and is actively raising funds to achieve this goal.